Minsuk Kwon - Search Results

Year	Number of Results
2003	2
2004	1
2008	1
2010	1
2011	1
2012	2
2013	2
2014	1
2015	1
2016	4
2017	1
2018	2
2019	4
2020	9
2021	9
2022	4
2023	0

1

Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer.

Kwon M, An M, Klempner SJ, Lee H, Kim KM, Sa JK, Cho HJ, Hong JY, Lee T, Min YW, Kim TJ, Min BH, Park WY, Kang WK, Kim KT, Kim ST, Lee J. Kwon M, et al. Cancer Discov. 2021 Sep;11(9):2168-2185. doi: 10.1158/2159-8290.CD-21-0219. Epub 2021 Apr 12. Cancer Discov. 2021. PMID: 33846173 Clinical Trial.

2

Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer.

Eum HH, Kwon M, Ryu D, Jo A, Chung W, Kim N, Hong Y, Son DS, Kim ST, Lee J, Lee HO, Park WY. Eum HH, et al. Among authors: kwon m. Exp Mol Med. 2020 Dec;52(12):1976-1988. doi: 10.1038/s12276-020-00538-y. Epub 2020 Dec 4. Exp Mol Med. 2020. PMID: 33277616 Free PMC article.

3

TOX-expressing terminally exhausted tumor-infiltrating CD8⁺ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.

Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Seo SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC. Han HS, et al. Among authors: kwon m. Cancer Lett. 2021 Feb 28;499:137-147. doi: 10.1016/j.canlet.2020.11.035. Epub 2020 Nov 27. Cancer Lett. 2021. PMID: 33249194

4

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.

Kwon M, Kim G, Kim R, Kim KT, Kim ST, Smith S, Mortimer PGS, Hong JY, Loembé AB, Irurzun-Arana I, Koulai L, Kim KM, Kang WK, Dean E, Park WY, Lee J. Kwon M, et al. J Immunother Cancer. 2022 Jul;10(7):e005041. doi: 10.1136/jitc-2022-005041. J Immunother Cancer. 2022. PMID: 35790315 Free PMC article. Clinical Trial.

5

Immune checkpoint inhibitors for cancer treatment.

Park J, Kwon M, Shin EC. Park J, et al. Among authors: kwon m. Arch Pharm Res. 2016 Nov;39(11):1577-1587. doi: 10.1007/s12272-016-0850-5. Epub 2016 Oct 21. Arch Pharm Res. 2016. PMID: 27770382 Review.

6

Plasmofluidic Disk Resonators.

Kwon MS, Ku B, Kim Y. Kwon MS, et al. Sci Rep. 2016 Mar 16;6:23149. doi: 10.1038/srep23149. Sci Rep. 2016. PMID: 26979929 Free PMC article.

7

Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma.

Kim AR, Choi SJ, Park J, Kwon M, Chowdhury T, Yu HJ, Kim S, Kang H, Kim KM, Park SH, Park CK, Shin EC. Kim AR, et al. Among authors: kwon m. Oncoimmunology. 2022 Jan 12;11(1):2026019. doi: 10.1080/2162402X.2022.2026019. eCollection 2022. Oncoimmunology. 2022. PMID: 35036078 Free PMC article.

8

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.

Hong JY, Cho HJ, Yun KH, Lee YH, Kim SH, Baek W, Kim SK, Lee Y, Choi YL, Kwon M, Kim HS, Lee J. Hong JY, et al. Among authors: kwon m. Cancer Res Treat. 2022 Sep 27. doi: 10.4143/crt.2022.251. Online ahead of print. Cancer Res Treat. 2022. PMID: 36164943 Free article.

9

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer.

Kim H, Kim H, Lee M, Kwon M, Hong JY, Lee J, Lim HY, Kang WK, Kim ST. Kim H, et al. Among authors: kwon m. J Cancer. 2021 Jul 25;12(18):5681-5686. doi: 10.7150/jca.62853. eCollection 2021. J Cancer. 2021. PMID: 34405028 Free PMC article.

10

Synchronized Cell Cycle Arrest Promotes Osteoclast Differentiation.

Kwon M, Kim JM, Lee K, Park SY, Lim HS, Kim T, Jeong D. Kwon M, et al. Int J Mol Sci. 2016 Aug 9;17(8):1292. doi: 10.3390/ijms17081292. Int J Mol Sci. 2016. PMID: 27517906 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results